CTLA4 and hepatitis A virus infection: Furthermore, hepatitis, an important irAE, was significantly decreased in the JX-594 and PD-1 inhibitor combination group, suggesting that the JX-594 and PD-1 inhibitor has potential benefits for reducing ICI-induced toxicity, especially that caused by the CTLA-4 inhibitor.